Meiji Holdings Co., Ltd. Meiji Holdings Co., Ltd. Financial Results - For the FYE March 2017 -  


Pharma: Steady sales growth in Japan and overseas

Prev. Page Next Page Download the PDF
The key strategies to increase income
Japan

 • Sales of Reflex, Sycrest and Bilanoa

JPY 29.9 billion, up 39% YoY

 • Maximize Reflex sales

Utilize the results of post-marketing clinical trials and other evidences

 • Grow sales of Sycrest and Bilanoa significantly

Approved long-term prescriptions in 2nd year of sales

Receiving high evaluations for the drugs

Strengthen MR promotions

 • Sales of generics: JPY 48.3 billion, up 14% YoY, details on the next slide

International
Contribute to income further

 • Growing steadily based on local currency

 • Expand sales in ASEAN region

 • Expand contracted manufacturing business